Log In
Print
BCIQ
Print
Print this Print this
 

Autologous T cell therapy against CD19 (KTE-C19)

  Manage Alerts
Collapse Summary General Information
Company Kite Pharma Inc.
DescriptionAutologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD19
Molecular Target CD19
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today